Mesoblast Share Price Today: Live Updates & Key Insights

Mesoblast share price today is $14.36, up -2.84%. The stock opened at $14.79 against the previous close of $14.78, with an intraday high of $14.89 and low of $14.24.

Mesoblast Share Price Chart

Mesoblast

us-stock
To Invest in {{usstockname}}
us-stock

Mesoblast Share Price Performance

$14.36 -0.0284(-2.84%) MESO at 23 Mar 2026 02:14 PM Biotechnology
Lowest Today 14.24
Highest Today 14.89
Today’s Open 14.79
Prev. Close 14.78
52 Week High 21.50
52 Week Low 9.61
Day’s Range: Low 14.24 High 14.89
52-Week Range: Low 9.61 High 21.50
1 day return -
1 Week return -1.84
1 month return -13.84
3 month return -25.88
6 month return -14.86
1 year return +0.2
3 year return +122.44
5 year return -22.9
10 year return -

Mesoblast Institutional Holdings

Legal & General Group PLC 0.53

BlackRock Inc 0.42

iShares Biotechnology ETF 0.40

Morgan Stanley - Brokerage Accounts 0.36

Susquehanna International Group, LLP 0.33

The Goldman Sachs Group Inc 0.32

SRS Capital Advisors Inc 0.16

UBS Group AG 0.15

Jane Street Group LLC 0.13

Citadel Advisors Llc 0.10

Bank of America Corp 0.09

Royal Bank of Canada 0.07

Penbrook Management LLC 0.07

Two Sigma Investments LLC 0.04

Prosperity Wealth Management Inc 0.04

LPL Financial Corp 0.04

Rialto Wealth Management, LLC 0.04

iShares Nasdaq US Biotech ETF USD Acc 0.03

L&G Pharma Breakthrough ETF 0.03

Fidelity Nasdaq Composite Index 0.02

Geode Capital Management, LLC 0.02

Quadrature Capital Limited 0.02

Citigroup Inc 0.02

Wells Fargo & Co 0.02

Polen 5Perspectives Small Growth Instl 0.01

China Universal NASDAQ Bio-Tch ETF(QDII) 0.01

Polen Capital US Small Com Gr USD Instl 0.00

ActivePassive International Equity ETF 0.00

Invesco Nasdaq Biotechnology ETF 0.00

ProShares Ultra Nasdaq Biotechnology 0.00

Plutos- Wealth One P 0.00

Xtrackers MSCI Genomic HC Inno ETF 1C 0.00

GF NASDAQ Bio-Tech Idx QDII USD A 0.00

Polen 5Perspectives Small Growth Composi 0.00

ST Dorsey Wright® Intl Momntm Tr 40 CA 0.00

ST Dorsey Wright® Intl Momntm Tr 41 CA 0.00

ST Dorsey Wright® Intl Momntm Tr 42 CA 0.00

Mesoblast Market Status

Strong Buy: 1

Buy: 2

Hold: 0

Sell: 0

Strong Sell: 0

Mesoblast Fundamentals

Market Cap 1936.97 M

PB Ratio 3.2197

PE Ratio 0.0

Enterprise Value 1884.95 M

Total Assets 784.68 M

Volume 259346

Mesoblast Company Financials

Annual Revenue FY25:17198000 17.2M, FY24:5902000 5.9M, FY23:7501000 7.5M, FY22:10211000 10.2M, FY21:7456000 7.5M

Annual Profit FY25:12068000 12.1M, FY24:-35168000 -35.2M, FY23:7501000 7.5M, FY22:10211000 10.2M, FY21:7456000 7.5M

Annual Net worth FY25:-102142000 -102.1M, FY24:-87956000 -88.0M, FY23:-81889000 -81.9M, FY22:-91347000 -91.3M, FY21:-98811000 -98.8M

Quarterly Revenue Q2/2025:7021000 7.0M, Q1/2025:7021000 7.0M, Q2/2024:1257000 1.3M, Q1/2024:1257000 1.3M, Q4/2023:1694000 1.7M

Quarterly Profit Q2/2025:-16227301 -16.2M, Q1/2025:-16227301 -16.2M, Q2/2024:-9581500 -9.6M, Q1/2024:-9581500 -9.6M, Q4/2023:-8002500 -8.0M

Quarterly Net worth Q2/2025:-27104000 -27.1M, Q1/2025:-27104000 -27.1M, Q2/2024:-27708500 -27.7M, Q1/2024:-27708500 -27.7M, Q4/2023:-16269500 -16.3M

About Mesoblast & investment objective

Company Information Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure; MPC-25-IC for the treatment or prevention of acute myocardial infarction; and Ryoncil for the treatment of pediatric SR-aGVHD; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Organisation Biotechnology

Employees 81

Industry Biotechnology

CEO Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Mesoblast FAQs

What is the share price of Mesoblast today?

The current share price of Mesoblast is $14.36.

Can I buy Mesoblast shares in India?

Yes, Indian investors can buy Mesoblast shares by opening an international trading and demat account with Motilal Oswal.

How to buy Mesoblast shares in India?

You can easily invest in Mesoblast shares from India by:

Can I buy fractional shares of Mesoblast?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Mesoblast?

Mesoblast has a market cap of $1936.97 M.

In which sector does Mesoblast belong?

Mesoblast operates in the Biotechnology sector.

What documents are required to invest in Mesoblast stocks?

To invest, you typically need:

What is the PE and PB ratio of Mesoblast?

The PE ratio of Mesoblast is N/A and the PB ratio is 3.22.